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Summary
 cell dysfunction is a central component of the
pathogenesis of type 2 diabetes. Using oligonucleo-
tide microarrays and real-time PCR of pancreatic is-
lets isolated from humans with type 2 diabetes versus
normal glucose-tolerant controls, we identified multi-
ple changes in expression of genes known to be im-
portant in  cell function, including major decreases
in expression of HNF4, insulin receptor, IRS2, Akt2,
and several glucose-metabolic-pathway genes. There
was also a 90% decrease in expression of the tran-
scription factor ARNT. Reducing ARNT levels in Min6
cells with small interfering RNA (siRNA) resulted in
markedly impaired glucose-stimulated insulin release
and changes in gene expression similar to those in
human type 2 islets. Likewise,  cell-specific ARNT
knockout mice exhibited abnormal glucose tolerance,
impaired insulin secretion, and changes in islet gene
expression that mimicked those in human diabetic is-
lets. Together, these data suggest an important role
for decreased ARNT and altered gene expression in
the impaired islet function of human type 2 diabetes.
Introduction
Type 2 diabetes is an epidemic disease affecting almost
200 million people worldwide (Zimmet et al., 2001). The
pathogenesis involves two core defects: insulin resis-
tance and impaired β cell function (Martin et al., 1992;
Weyer et al., 1999; DeFronzo et al., 1992). β cell dys-
function is a critical component of all forms of diabetes.
In type 1 diabetes, this occurs as a result of autoim-
mune β cell destruction, whereas in type 2 diabetes, β
cell mass may be normal or only slightly reduced early
in the disease (Clark et al., 1988), although there are
marked functional defects, including impaired first-*Correspondence: c.ronald.kahn@joslin.harvard.eduphase insulin secretion, loss of pulsatility of insulin
secretion, altered insulin/proinsulin ratio, and increased
β cell apoptosis (Porte and Kahn, 2001; Del Prato et al.,
2002; Gerich, 1998; Gumbiner et al., 1996; Butler et al.,
2003). Many substantial advances toward the under-
standing of peripheral insulin resistance have been
made in animal models and in humans (Bruning et al.,
1997; Lauro et al., 1998; Nandi et al., 2004; Sreekumar
et al., 2002; McCarthy and Froguel, 2002; Mauvais-Jar-
vis and Kahn, 2000; Petersen et al., 2004). However, the
mechanisms underlying β cell failure in humans are less
well understood, partly due to difficulty accessing the
pancreas and the small contribution (<2%) of islets to
the total pancreatic mass (Kloppel et al., 1985).
Important understanding of the genetic control of β
cell function has come from maturity-onset diabetes of
the young (MODY) (Bell and Polonsky, 2001; Froguel
and Velho, 2001; Habener and Stoffers, 1998; Polon-
sky, 1995). In these relatively rare autosomal dominant
forms of diabetes, mutations in one of six identified
genes leads to impaired insulin secretion and early-
onset diabetes. The MODY genes are five transcription
factors (HNF1α, HNF1β, HNF4α, PDX-1/IPF-1, and Neu-
roD1/Beta2) and glucokinase.
In addition, the glucose-sensing and insulin-signaling
pathways have been shown to play important roles in
β cell function. These pathways include the facilitative
glucose transporters, especially GLUT2, glucokinase
(which phosphorylates glucose to G6P), and several
enzymes of the glycolytic pathway that metabolize glu-
cose, resulting in an increased ATP:ADP ratio, mem-
brane depolarization, and insulin release. Although glu-
cose uptake in β cells is insulin independent, studies in
animal and in vitro models have indicated important
roles for insulin signaling in maintenance of normal glu-
cose-responsive insulin secretion. Thus, genetically
modified mice lacking insulin receptors, IRS2, or the
serine kinase Akt2 exhibit marked alterations in glucose
sensing, insulin secretion, and/or altered β cell growth
(Kulkarni et al., 1999a; Withers et al., 1998; Cho et al.,
2001).
In the present study, we sought to identify defects
in islets isolated from humans with type 2 diabetes by
examining gene-expression profiles using oligonucleo-
tide microarrays and real-time polymerase chain reac-
tion (PCR). These revealed decreased expression of
several genes known to be associated with defective β
cell function, including HNF4α and glucose-sensing
and insulin-signaling genes. In addition, islets from hu-
mans with type 2 diabetes demonstrated marked
downregulation of the aryl hydrocarbon receptor
nuclear translocator (ARNT) (also called hypoxia-induc-
ible factor 1 β or HIF1β).
ARNT is a member of the basic helix-loop-helix Per/
AhR/ARNT/Sim (bHLH-PAS) family of transcription fac-
tors and is essential for normal embryonic development
(Abbott and Buckalew, 2000; Kozak et al., 1997; Mal-
tepe et al., 1997). All bHLH-PAS proteins function as
obligate heterodimers, with ARNT acting as the general
partner for other members of the family, including
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338HIF1α, HIF2α, HIF3α, and AhR. HIF proteins mediate
ssignal transduction in response to conditions of hyp-
oxia, and AhR responds to certain environmental toxins e
Hsuch as polycyclic aromatic hydrocarbons and the no-
torious dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (Ko- (
dzak et al., 1997; Kewley et al., 2004).
We find that knockdown of ARNT in cultured Min6 u
cells using small interfering RNA (siRNA) and β cell-
specific knockout of ARNT in mice produces both de- a
(fects in glucose-stimulated insulin release and alter-
ations in islet gene expression that mimic those in islets b
Iof humans with type 2 diabetes. Together, these dif-
ferent models suggest an important role for ARNT and h
paltered gene expression in impaired β cell function and
the pathogenesis of human type 2 diabetes. 0
p
rResults
t
Microarray Analysis
ecRNA prepared from islets of seven normal and five
wtype 2 diabetic patients was hybridized to Affymetrix
gU133A and B microarrays. Demographic characteris-
ptics are shown in Table S1 in the Supplemental Data
(available with this article online. Of the w44,928 genes
0and ESTs represented on these chips, 370 showed dif-
tferences in expression at the p < 0.01 level (Table S2).
Of these, 243 were upregulated in diabetic subjects rel-
mative to normal, and 137 were downregulated. All of the
(microarray data will be available on the website of the
aDiabetes Genome Anatomy Project (DGAP) at http://
iwww.diabetesgenome.org.
cNone of the 13 genes that were recently reported
eto best differentiate acinar and islet contributions to
tmRNA (Cras-Meneur et al., 2004) differed, indicating
cequivalent islet purification in the two groups (Figure
p1A). As expected, expression of insulin, glucagon, so-
pmatostatin, and pancreatic polypeptide mRNAs in hu-
sman islets was high but did not differ significantly
pbetween groups (Figure 1B). Figure 1C shows array ex-
tpression of a number of non-MODY transcription fac-
tors known to be associated with β cell development
iand function. None of these was significantly altered,
ralthough Foxa2/HNF3β and Pax4 both showed trends
ato increased expression in diabetics (p = 0.06). Expres-
asion of neurogenin3 was low and did not differ be-
ftween groups.
gMAPPFinder 2.0 analysis of the microarray data iden-
stified the group of RNA-processing genes as signifi-
ecantly altered (Figure S1). No other group of genes was
iidentified using this approach. Therefore, we focused
iour initial attention on families of genes that have pre-
tviously been linked to β cell function.
c
sExpression of MODY, Glucose-Sensing, and Insulin-
Signaling Genes Was Altered in Human Islets
Three groups of genes that have been shown to affect A
fglucose-stimulated insulin secretion are the MODY
genes, glucose-uptake and -metabolism genes, and sev- B
ieral insulin-signaling genes. Expression of genes from
these groups was measured by both microarray and o
Pquantitative real-time PCR. For simplicity, the quantitative
RT-PCR data are presented here, but as noted above, n
nthe array data are available at the DGAP website.Of the six MODY genes, HNF4α was markedly and
ignificantly decreased in human diabetic islets, with
xpression at 18% of control (p = 0.002) (Figure 2A).
NF1α showed a trend toward decreased expression
p = 0.08). Expression of other MODY genes did not
iffer significantly, although there was wide interindivid-
al variability in PDX-1 and glucokinase.
mRNAs for the glucose transporters GLUT1, GLUT2,
nd GLUT3 (Figure 2B), as well as GLUT9 and GLUT10
data not shown), were all clearly detectable in islets,
ut there were no significant differences in expression.
nterestingly, in human islets, GLUT1 was much more
ighly expressed than GLUT2. By RT-PCR, GLUT1 ex-
ression in controls was 4.4 times that of GLUT2 (p =
.037). Markedly higher expression of GLUT1 com-
ared to GLUT2 in human islets has been previously
eported (De Vos et al., 1995) and is a potentially impor-
ant difference between human and rodent islets.
In contrast to glucose-transporter expression, sev-
ral downstream enzymes in the glycolytic pathway
ere significantly decreased in diabetic islets, including
lucose-6-phosphate isomerase (G6PI), aldolase (Aldo),
hosphofructokinase (PFK), and phosphoglucomutase
PGM) at 16%, 18%, 19%, and 11% of control (p =
.002, p < 0.0001, p < 0.0001, and p < 0.0001, respec-
ively).
Among the insulin-signaling genes, insulin-receptor
RNA was significantly lower in subjects with diabetes
23% of control, p = 0.027) (Figure 2C). In addition, IRS2
nd Akt2 mRNAs were significantly and markedly lower
n the diabetic subjects (9%, p < 0.0001, and 16% of
ontrol, p = 0.008, respectively). On the other hand,
xpression of SHIP2, a phosphatidylinositol phospha-
ase that inhibits insulin signaling, was significantly in-
reased in islets of the type 2 diabetics (81% increase,
= 0.04). These changes would be likely to lead to im-
aired insulin signaling in diabetic islets. There were no
ignificant differences in expression of proinsulin, IRS4,
hosphatidylinositol (PI) 3-kinase subunits, or Akt1 be-
ween the two groups (data not shown).
In mice, the two alternately spliced isoforms of the
nsulin receptor have been suggested to play different
oles in regulation of islet gene expression (Leibiger et
l., 2001). Furthermore, some studies have suggested
n altered ratio of expression of insulin-receptor iso-
orms in muscle of humans with type 2 diabetes (Nor-
ren et al., 1993). Semiquantitative PCR using primers
elected to amplify both A (minus exon 11) and B (plus
xon 11) isoforms (Entingh et al., 2003) revealed that
soform A was the dominantly expressed form in human
slets and confirmed the decrease in total insulin-recep-
or mRNA, but the ratio of isoforms did not differ signifi-
antly between the diabetics and controls (data not
hown).
RNT Expression Was Decreased in Islets
rom Humans with Type 2 Diabetes Mellitus
y microarray, the most significantly decreased gene in
slets from people with type 2 diabetes was ARNT, 18%
f control levels, p = 0.000012, Figure 2D. Real-time
CR confirmed a substantial and highly statistically sig-
ificant decrease in ARNT, with expression at 10.2% of
ormal islets, p < 0.0000001, Figure 2E. Among the
ARNT and Altered Gene Expression in β Cells
339Figure 1. Expression of Islet Genes, Hor-
mones, and Islet Transcription Factors Did
Not Differ in Normal Glucose-Tolerant or Dia-
betic Humans
RNA was purified from pancreatic islets iso-
lated from five people with type 2 diabetes
and seven with normal glucose tolerance.
(A) By Affymetrix oligonucleotide microarray,
the 13 genes reported to best differentiate
between islet and acinar pancreatic tissue
(Cras-Meneur et al., 2004) did not differ be-
tween diabetic and control subjects, sug-
gesting equivalent islet purification. Gene
1 = carboxypeptidase A1; 2 = protease ser-
ine 2; 3 = protease serine 1; 4 = amylase
α-2A; 5 = carboxypeptidase B1; 6 = elastase
3A; 7 = pancreatic colipase; 8 = carboxypep-
tidase A2; 9 = pancreatic lipase; 10 = car-
boxyl ester lipase; 11 = elastase 3B; 12 =
chymotrypsinogen; 13 = phospholipase A2,
group IB.
(B) Expression of pancreatic hormones did
not differ significantly between the diabetic
and normal glucose-tolerant groups. By ar-
ray, expression of preproinsulin was 186,000
in the diabetic group. The median array ex-
pression was 1,500, indicating the expected
very high level of preproinsulin expression
in islets.
(C) Expression of a number of important islet
transcription factors did not differ signifi-
cantly in diabetic islets as determined by Af-
fymetrix microarray analysis. There were
trends toward increased expression of Foxa2/
HNF3β (p = 0.06) and Pax4 (p = 0.06).
Bars show fold change in microarray results
compared to control subjects, and error bars
indicate ± 1 SEM. Black bars = control; gray
bars = type 2 diabetes.bHLH-PAS family members, AhR, BMAL1, HIF1α, and
HIF2α/EPAS1 were detected in human islets by micro-
array and real-time PCR. Of these, AhR, BMAL1, and
HIF1α were also significantly decreased (Figure 2F).
Small Interfering RNA Impaired Glucose-Stimulated
Insulin Release and mRNA Expression in Min6 Cells
To determine the role of ARNT in a glucose-responsive
β cell-derived model, Min6 cells were treated with
siRNA directed against ARNT or scrambled-siRNA con-
trol. As shown in Figure 3A, siRNA treatments de-
creased ARNT protein with varying effectiveness. This
was paralleled by decreases in ARNT mRNA (data not
shown). Scrambled siRNA (control, group 1) had no ef-
fect on ARNT protein levels. Among the six active
siRNAs tested, there were two levels of effect: an inter-
mediately effective group (group 2), which caused a
moderate decrease in ARNT (approximately 40%) and
the most effective siRNAs, which markedly reduced
ARNT (>80% decrease, group 3). When each of these
was assessed for effect on β cell function, both the
moderately effective and most effective siRNAs pro-duced marked reductions in glucose-stimulated insulin
secretion from Min6 cells. Group 2 produced a de-
crease of approximately 50% in the stimulatable com-
ponent of insulin release (p < 0.01 by ANOVA for
repeated measures), whereas group 3 abolished glu-
cose-stimulated insulin release (p < 0.001 by ANOVA)
(Figure 3B).
Real-time PCR of RNA isolated from Min6 cells re-
vealed that siRNA treatment also led to significant de-
creases in the expression of HNF4α (60% decrease, p =
0.012) and HNF1α (68% decrease, p < 0.0001) (Figure
3C); G6PI (35% decrease, p = 0.039), aldolase (50% de-
crease, p = 0.048), and PFK (59% decrease, p = 0.047)
(Figure 3D); and insulin receptor (88% decrease, p =
0.044), IRS2 (78% decrease, p < 0.001), and Akt2 (97%
decrease, p < 0.0001) (Figure 3E). Together, these marked
changes in gene expression would be expected to impair
β cell function, glucose metabolism, and glucose-respon-
sive insulin secretion, which was seen in Figure 3B.
The changes in mRNA expression in the Min6 cells
with reduced ARNT expression closely paralleled the
changes observed in the human islets from people with
Cell
340Figure 2. mRNA Expression Was Altered in
Human Pancreatic Islets Isolated from Sub-
jects with Type 2 Diabetes
(A) Real-time PCR was used to measure
mRNA expression in human pancreatic is-
lets, with correction for expression of the
control gene TATA-box binding protein (TBP).
Of the MODY genes, HNF4α was signifi-
cantly decreased in diabetic islets. Glucoki-
nase, PDX-1, and HNF1α were lower but did
not reach significance due to wide interindi-
vidual variability.
(B) By real-time PCR, the expression levels
of glucose transporters GLUT1, GLUT2, and
GLUT3 in human islets did not differ signifi-
cantly. However, the expression of the en-
zymes involved in several successive steps
in the glucose metabolic pathway was signif-
icantly decreased: glucose-6-phosphoisom-
erase (G6PI), phosphofructokinase (PFK),
and phosphoglucomutase (PGM).
(C) Expression of insulin receptor, IRS2, and
Akt2 was significantly decreased in type 2
diabetes. Additionally, expression of the
PIP3 phosphatase SHIP2 was increased.
(D) By microarray, ARNT was detectable in
islets isolated from 7 of 7 people with normal
glucose tolerance but was below back-
ground levels in 5 of 5 subjects with type 2
diabetes.
(E) Decreased ARNT was confirmed by real-
time PCR, with ARNT expression in diabetic
subjects being 10.2% of that in controls (p =
2.5 × 10−9).
(F) Expression of other bHLH/PAS family
members was decreased in diabetic human
pancreatic islets, including aryl hydrocarbon
receptor (AhR), BMAL1, and hypoxia-induc-
ible factor 1 α (HIF1α).
Error bars are ± 1 SEM. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001; *****p < 0.00001.
Black bars = normal glucose tolerance; gray
bars = type 2 diabetic subjects.type 2 diabetes. When the real-time PCR fold changes G
iwere plotted against each other, there was a strong and
highly significant correlation between the change in T
stype 2 islets and the change in siRNA-treated Min6
cells for genes with a putative ARNT binding site in the d
wfirst 2 kb of their promoter regions (r2 = 0.69 and p =
0.006, Figure 3F). d
tTo examine which ARNT partner (or partners) was
important in the effect upon β cell function, Min6 a
ncells were treated with siRNAs directed against HIF1α,
HIF2α, or AhR. Each of these was effective, achieving c
(>65% decrease in expression (Figure 3G). At low
glucose concentration, knockdown of the AhR led to m
ma small but significant decrease in insulin release,
whereas knockdown of HIF1α and HIF2α was without w
meffect (Figure 3H). At 33 mM glucose, knockdown of
HIF1α, HIF2α, and AhR each independently produced s
gsmall but significant decreases in insulin release, but
none of these achieved the same magnitude of de- a
ocrease seen with ARNT knockdown (p < 0.01), suggest-
ing that the effect of decreased ARNT may result from b
closs of function of multiple of these bHLH-PAS hetero-
dimers in β cells. slucose Tolerance and Insulin Secretion
n -ARNT Mice
o determine the role of ARNT in vivo, mice with β cell-
pecific knockout of ARNT (β-ARNT) were created as
escribed in Experimental Procedures. β-ARNT mice
ere born at the expected frequencies, were fertile, and
id not differ in weight or length from their floxed con-
rol littermates. However, on glucose-tolerance testing
t 9–11 weeks of age, female β-ARNT mice showed sig-
ificantly higher serum glucose values with 1 g/kg glu-
ose load (Figure 4A) as well as with 2 g/kg of glucose
Figure 4B) (both p < 0.01 by ANOVA). Female β-ARNT
ice had fasting insulin levels similar to those in control
ice, but first-phase glucose-stimulated insulin release
as totally abolished (Figure 4D, p < 0.01). Further-
ore, female β-ARNT mice had no augmentation of in-
ulin secretion following addition of arginine to the
lucose stimulation, while controls displayed a clear
ugmentation (Figure 4F, p < 0.01). Male β-ARNT mice,
n the other hand, had a milder phenotype with slightly,
ut significantly, higher glucose values compared to
ontrols (Figure 4C) and a normal insulin-secretory re-
ponse to glucose (Figure 4E). Male β-ARNT mice ex-
ARNT and Altered Gene Expression in β Cells
341Figure 3. Decreasing ARNT In Vitro with Small Interfering RNA (siRNA) Impairs Glucose-Stimulated Insulin Release (GSIR) in Min6 Cells
(A) Western immunoblot of ARNT protein following treatment with either scrambled-siRNA controls (Scr) or six different anti-ARNT siRNAs
for 48 hr. siRNAs were grouped as moderately effective (group 2) and highly effective (group 3).
(B) Cells treated with control siRNA showed normal glucose-stimulated insulin release. Compared to Scr controls, cells treated with group 2
siRNAs showed significant impairment of glucose-stimulated insulin release (p < 0.01), and cells treated with group 3 siRNAs had no response
to glucose stimulation (p < 0.001).
(C–E) Min6 cells treated with anti-ARNT siRNA had altered gene expression, measured by real-time PCR.
(C) Among the MODY genes, decreased ARNT was associated with significantly decreased HNF4α and HNF1α.
(D) Expression of glucose-6-phosphoisomerase (G6PI), aldolase (Aldo), and phosphofructokinase (PFK) were significantly decreased following
siRNA treatment.
(E) siRNA treatment led to decreased expression of insulin receptor (IR), insulin receptor substrate-2 (IRS2), and Akt2.
(F) For genes with a potential ARNT binding site in the promoter, the fold change in mRNA expression in type 2 human islets was correlated
with the fold change in siRNA-treated Min6 cells, r2 = 0.69.
(G) To examine the role of potential ARNT partners, Min6 cells were treated with RNAi directed against HIF1α, HIF2α, AhR, or ARNT for 48 hr.
These caused >65% decreases in mRNA expression.
(H) Insulin release was measured after RNAi treatment. AhR RNAi decreased basal insulin secretion, and RNAi directed against HIF1α, HIF2α,
and AhR significantly decreased insulin release at 33 mM glucose; however, none of these was as effective as ARNT knockdown.
Error bars are ± 1 SEM. *p < 0.05; **p < 0.01 versus control; ***p < 0.001; ††p < 0.01 versus control at 0 mM glucose; ‡‡p < 0.01 versus ARNT
siRNA at 30 mM glucose. Black bars = scrambled siRNA; gray bars = active siRNA.
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342Figure 4. Glucose Tolerance and Insulin Secretion Were Abnormal in 9- to 11-Week-Old Mice with β Cell-Specific Deletion of ARNT
(β-ARNT Mice)
(A) Intraperitoneal glucose-tolerance testing (GTT) with a 1 g/kg glucose load led to significantly greater glucose excursion in female
β-ARNT mice.
(B) During GTT with 2 g/kg glucose load, female β-ARNT mice showed significantly higher glucose levels than floxed control littermates (p <
0.01 by ANOVA for repeated measures).
(C) Male β-ARNT mice had slightly, but significantly, higher glucose levels than controls when large numbers of mice were compared.
(D) Glucose-stimulated insulin secretion (GSIS) was markedly abnormal in female β-ARNT mice, with total loss of first-phase insulin secretion
(p < 0.01).
(E) Male mice had preserved GSIS.
(F) Arginine augmentation of GSIS was normal in floxed control mice but was lacking in female β-ARNT mice (p < 0.01).
(G) Male β-ARNT mice showed mild impairment of arginine-augmented GSIS (p < 0.05).
Error bars are ± 1 SEM. *p < 0.05; **p < 0.01. Solid line = control mice; dashed line = β-ARNT mice.
ARNT and Altered Gene Expression in β Cells
343hibit a 40% reduction in peak levels of insulin following
combined arginine and glucose stimulation compared
to controls (p < 0.05, Figure 4G).
Islets from -ARNT Knockout Mice Display Defective
Glucose-Stimulated Insulin Release and Altered
mRNA Expression
To determine the basis of the defect in glucose-stim-
ulated insulin secretion in the β-ARNT mice, islets from
β-ARNT and control animals were examined. Isolated
islets were stained with a cocktail for insulin, DAPI, and
ARNT. As shown, ARNT deletion was highly effective in
the knockout mice (Figure 5A). β cell mass was exam-
ined by an observer blinded to mouse genotype and
did not differ between β-ARNT and control mice (Figure
5B). Islet isolation gave similar yields of 227 ± 19 and
236 ± 12 islets in β-ARNT and control mice, respectively.
Total insulin content did not differ between β-ARNT and
control mice for either female or male mice (Figure 5C).
Using islets from either females or males, insulin re-
lease was low and equal at low glucose concentrationsFigure 5. Insulin Release Was Abnormal in
Islets Isolated from β-ARNT Mice
Equal numbers of islets were selected for in-
sulin-secretion and -content studies by in-
vestigators blinded to mouse genotype.
(A) Islets isolated from β-ARNT and control
mice were used for immunohistochemistry
to confirm efficacy of ARNT deletion.
(B) β cell mass was quantified by an ob-
server blinded to mouse genotype and did
not differ significantly between control and
β-ARNT mice for either males or females.
(C) Total insulin content also did not differ
between β-ARNT and control mice for either
female or male mice.
(D) Insulin release was significantly lower
from female β-ARNT islets at glucose con-
centrations of 8.3 and 11 mM and showed a
trend toward lower secretion at 25 mM
glucose.
(E) In male mice, insulin release was also sig-
nificantly lower from β-ARNT islets than from
floxed control islets at glucose concentra-
tions of 11 and 25 mM.
Error bars are ± 1 SEM. *p < 0.05; **p < 0.01.(3 or 5 mM). However, at glucose concentrations of 8.3
and 11 mM, insulin release from female β-ARNT islets
was significantly lower than in controls (p < 0.01 and p <
0.05, respectively) (Figure 5D). This trend continued at
25 mM glucose, but the difference did not achieve sta-
tistical significance at this high glucose level. In male
β-ARNT mice, insulin release was also lower at both 11
and 25 mM glucose (Figure 5E).
RNA was isolated from the remaining islets and ana-
lyzed by real-time PCR. The results for male and female
mice did not differ significantly, so they are presented
together. As shown in Figure 6A, of the genes associ-
ated with MODY in humans, HNF4α was substantially
and significantly decreased (92% decrease, p < 0.0001).
Expression of glucose transporters GLUT1 and GLUT2
was not altered. However, G6PI and aldolase were sig-
nificantly decreased (46%, p = 0.044 and 54%, p =
0.048, respectively) (Figure 6B). Insulin-receptor ex-
pression was decreased by 46% (p < 0.0001), and there
was a 73% decrease in Akt2 expression (p = 0.007) (Fig-
ure 6C). Again, the changes observed in mRNA expres-
sion in β-ARNT islets paralleled those seen in human
Cell
344Figure 6. By Real-Time PCR, mRNA Expres-
sion in β-ARNT Mouse Islets Was Abnormal
and Mimicked Those Changes Seen in Hu-
man Islets from Type 2 Diabetic Subjects and
Anti-ARNT siRNA-Treated Min6 Cells
There were no significant differences in gene
expression between males and females, so
results are shown together.
(A) Of the MODY genes, HNF4α was highly
significantly decreased in β-ARNT islets
compared to floxed controls.
(B) Of the glucose-uptake and -metabolism
genes, glucose-6-phospho-isomerase (G6PI)
and aldolase (Aldo) were significantly de-
creased in islets from knockout mice. Phos-
phofructokinase (PFK) expression was sig-
nificantly increased.
(C) Insulin-receptor and Akt2 expression
were significantly decreased in islets from
β-ARNT mice.
(D) There was a significant correlation be-
tween the fold change in mRNA expression
in type 2 human islets and the fold change
in the islets of the β-ARNT mice (r2 = 0.36;
p = 0.038).
Error bars are ± 1 SEM. *p < 0.05; **p < 0.01;
****p < 0.0001. Black bars = floxed control
islets; gray bars = β-ARNT islets.pancreatic islets and those in Min6 cells treated with 1
(siRNA to decrease ARNT. The fold change of gene ex-
pression in human type 2 islets plotted against fold e
change in βARNT mouse islets is shown in Figure 6D
for genes with a putative ARNT binding site in the first s
m2 kb of their promoter regions and was significant (r2 =
0.36, p = 0.038). Interestingly, for the mRNAs examined, p
rthe results for male and female mice did not differ sig-
nificantly, suggesting that the ability of male mice to i
dmaintain near-normal glucose tolerance and insulin
secretion depends on compensation by some other
component of the insulin-secretion or insulin-action D
pathway.
Among potential ARNT partners, expression of mRNAs I
for AhR, BMAL1, HIF1α, and HIF2α/EPAS1 were clearly h
detectable in mouse islets (data not shown). t
(
GComparison to Other Mouse Models of Diabetes
RNA was isolated from islets of three other mouse i
imodels of islet dysfunction and diabetes: ob/ob mice,
db/db mice, and β cell-specific insulin-receptor knock- e
iout mice (βIRKO), all at 10–12 weeks of age. The first
two models have hyperglycemia (456–464 mg/dl versus m95–286 mg/dl), while βIRKO mice are normoglycemic
197 ± 18 mg/dl versus 187 ± 33 mg/dl in controls), as
xpected at this young age.
There was a trend toward decreased ARNT expres-
ion in βIRKO mice (74% of expression in IR-lox ani-
als, p = 0.07) and no significant change in ARNT ex-
ression in db/db or ob/ob mice (Figure 7). These
esults suggest that the substantial decrease in ARNT
n human islets is not likely to be mediated solely by
iabetes, hyperglycemia, or insulin resistance.
iscussion
t is well known that humans with type 2 diabetes ex-
ibit marked defects in β cell function, the most charac-
eristic of which is impaired first-phase insulin secretion
Edlund, 2001; Del Prato et al., 2002; Gerich, 1998;
umbiner et al., 1996; Butler et al., 2003). This defect
s intrinsic, as demonstrated by recent studies using
slets isolated from subjects with type 2 diabetes (An-
llo et al., 2005). Our data show that pancreatic islets
solated from patients with type 2 diabetes also exhibit
ultiple alterations in gene expression. The magnitude
ARNT and Altered Gene Expression in β Cells
345Figure 7. ARNT Expression in Islets Isolated from Other Mouse
Models of Diabetes and siRNA Treatment to Identify Potential
ARNT Partners in Min6 Cells
Pancreatic islets were isolated from IR-lox mice and β cell-specific
insulin-receptor knockout (βIRKO), ob control (ob-c), ob/ob, db
control (db-c), and db/db mice aged 10–12 weeks, and RNA was
isolated for real-time PCR. As shown, βIRKO mice showed a trend
toward decreased ARNT expression (74% of control, p = 0.07),
whereas ob/ob mice and db/db mice had no significant changes in
ARNT expression. Error bars are ± 1 SEM.of some of these changes is quite impressive and in-
volves a number of genes demonstrated to affect β cell
function, including HNF4α, the insulin receptor, IRS2,
Akt2, and several enzymes of the glycolytic pathway.
HNF4α is a MODY gene, and studies in knockout mice
show that decreased levels of insulin receptor, IRS2, or
Akt2 can lead to altered glucose sensing and defective
insulin secretion (Bell and Polonsky, 2001; Kulkarni et
al., 1999a; Withers et al., 1998; Cho et al., 2001).
In an effort to identify an upstream regulator of these
changes, we examined the mRNA expression of tran-
scription factors. While most were unchanged, there
was a substantial and highly significant decrease in ex-
pression of ARNT. In vitro studies in cultured β cells
using siRNA to decrease ARNT resulted in severe im-
pairment of glucose-stimulated insulin secretion and al-
terations in mRNA expression that largely paralleled
those seen in human type 2 diabetic islets. Likewise, β
cell-specific deletion of ARNT in mice led to significant
abnormalities in glucose metabolism and insulin secre-
tion and a number of changes in RNA expression in
isolated islets, which also paralleled those seen in hu-
man pancreatic islets. These data suggest that changes
in gene expression could lead to the altered insulin
secretion in human type 2 diabetes and that ARNT is a
likely upstream regulator of many of these changes.
ARNT is essential for the normal function of HIF1α,
HIF2α, and the aryl hydrocarbon receptor (AhR). These
heterodimeric complexes are required for cellular re-
sponses to hypoxia (HIF proteins) and environmental
toxins (AhR), respectively (Kozak et al., 1997; Kewley et
al., 2004). ARNT-containing dimers have been reported
to regulate expression of many genes. With short DNA
consensus binding sites for ARNT hetero- and homodi-
mers, there are more than 13,000 putative ARNT bind-
ing sites in promoters in the human genome. Many ofthese promoters have multiple potential binding sites.
Thus, a substantial decrease in ARNT could result in
many alterations in gene expression. Many of the genes
found to be altered in association with decreased ARNT
in this study have putative ARNT-dimer consensus
binding sites in their promoters (including HNF4α,
HNF1α, Akt2, G6PI, PFK, and aldolase), consistent with
a direct role of ARNT-containing dimers in the regula-
tion of their expression. Preliminary results using chro-
matin immunoprecipitation suggest a direct role of
ARNT-HIF dimers in the regulation of expression of
these glycolytic enzymes.
It has been previously reported that ARNT regulates
transcription of a number of genes involved in the
pathogenesis of diabetes. These include mRNAs cod-
ing for proteins involved in glucose metabolism and
genes involved in vascular function and hypoxic re-
sponse, including vascular endothelial growth factor
(VEGF), plasminogen activator inhibitor 1 (PAI1), and
erythropoietin (EPO) (Zelzer et al., 1998; Salceda et al.,
1996; Forsythe et al., 1996; Okino et al., 1998). ARNT
has also been shown to regulate aldolase in hepatoma
and breast carcinoma cells (Zelzer et al., 1998; Salceda
et al., 1996). The lack of decrease in GLUT1 with de-
creased ARNT was surprising, in that HIF1α is known
to regulate GLUT1. RNAi directed against HIF1α in Min6
cells resulted in a decrease in GLUT1 expression (data
not shown), suggesting that diminishing ARNT may
lead to other compensatory changes that oppose the
HIF1α effect.
One of the genes that appears to be regulated by
ARNT is HNF4α, which was decreased in association
with decreased ARNT in human islets, as well as in cells
after RNAi knockdown and in knockout mice. While
HNF4α is a MODY gene and decreased HNF4α is likely
to have contributed to the phenotype by inducing sec-
ondary gene-expression changes, mice with β cell-spe-
cific deletion of HNF4α have mild abnormalities in β cell
function (Gupta et al., 2005; F.J.G., unpublished data).
This suggests that the changes in the β-ARNT mice are
not mediated solely via HNF4α. This is not surprising
since ARNT dimerizes with multiple transcription part-
ners to alter the expression of target genes.
Dioxins are potent environmental toxins that signal
through the ARNT-AhR heterodimer. Dioxin exposure is
associated with an increased risk of type 2 diabetes in
women (Fierens et al., 2003; Pesatori et al., 2003). The
data in men are less clear, with some studies suggest-
ing an increased risk of diabetes following dioxin expo-
sure (Fierens et al., 2003; Kim et al., 2003) and some
not (Pesatori et al., 2003; Michalek et al., 2003). This
parallels our findings in that the phenotype of the β-ARNT
mice was greater in females than in males. Whether the
alteration in ARNT in human type 2 diabetes is the re-
sult of exposure to an environmental toxin will require
further study.
The presence of sexual dimorphism is observed in
almost all mouse models of diabetes. In most models of
type 2 diabetes, including those generated by altering
insulin signaling, there is a male predominance in the
phenotype. In the NOD mouse model of type 1 diabetes
in which there is autoimmune β cell destruction, there
is a strong female predominance in the development of
diabetes, even though both genders develop lympho-
Cell
346cytic infiltration of the islets (Kikutani and Makino, o
1992). The specific factors leading to the sexual dimor- h
phism remain largely unexplained in virtually all of s
these models. 2
ARNT has multiple potential partners, and which of s
these is most important in β cells remains to be deter- e
mined. By real-time PCR, mRNA expression of AhR, g
BMAL1, HIF1α, and HIF2α was clearly detectable in hu- a
man islets, mouse islets, and Min6 cells. ARNT2 ex- m
pression has not been reported in pancreas. Mice with a
inactivating mutations in AhR, BMAL1, HIF1α, and
HIF2α/EPAS1 have been generated. A small proportion a
(23%) of female AhR null mice develop glucose intoler- 2
ance at 7 months of age, suggesting that the ARNT- p
AhR dimer plays a role in normal β cell function (Thack- t
aberry et al., 2003). However, the phenotype is less t
pronounced in the AhR mice, less penetrant, and oc- s
curs at an older age than in our mice, suggesting an h
additional pathogenic component in the β-ARNT mice. g
BMAL1 null mice, on the other hand, have lower serum p
glucose and insulin levels, suggesting that inactivation d
of the ARNT-BMAL1 heterodimer is not responsible for t
the diabetic phenotype seen in our animal model (D.
EKennaway, personal communication). Since these data
are at present only available for male mice, it will be of
Iinterest to determine whether the female BMAL1 null
smice have a different phenotype, given the dimorphic (
phenotype that we have observed. m
The HIF1α null mutation is embryonic lethal, and thus j
dthe glucose homeostasis of this model is unknown, but
othere are no reported major abnormalities in pancreatic
edevelopment. Similarly, the HIF2α null mouse shows
ihigh embryonic/neonatal lethality, and glucose-homeo-
d
stasis data have not been reported. HIF1α protein and f
HIF2α protein are undetectable in Min6 cells in the
basal state but are clearly detected upon treatment j
fwith the hypoxic mimics such as desferrioxamine (DFO)
Uor CoCl (data not shown). In preliminary coimmuno-
jprecipitation studies in Min6 cells, we find that ARNT
dassociates with AhR under normoxic conditions and,
w
following DFO treatment, also associates with HIF1α p
and 2α. Since islets in vivo are in a slightly hypoxic en- s
vironment (pO2 31–37 mm Hg [Carlsson et al., 1998]), (
there may be increased expression of HIF proteins in
Athe pancreas in vivo that mimics the latter condition.
TOur preliminary studies using siRNA in Min6 cells sug-
cgest that the loss of HIF1α, HIF2α, and AhR individually t
produce only minor effects of glucose-stimulated insu- h
lin secretion, suggesting that the altered insulin secre- (
tion observed within islets and Min6 cells with de- g
pcreased ARNT may be due to the combined effects of
wthese transcription factors rather than one heterodimer
in particular.
s
A possible driving force for additional changes in U
gene expression seen in human islets is the altered ex- h
pression of insulin-signaling proteins. Mice with β cell- w
specific knockout of the insulin receptor or global g
aknockout of IRS2 or Akt2 develop diabetes with early β
acell failure (Kulkarni et al., 1999a; Withers et al., 1998;
aCho et al., 2001). It is therefore very interesting that the
m
mRNAs encoding these insulin-signaling proteins were m
significantly decreased in the type 2 diabetic subjects, u
suggesting an important role for alterations in this path- r
away in human diabetes. Furthermore, SHIP2, a memberf the inositol polyphosphate 5-phosphatase family,
as been shown to be a negative regulator of insulin
ignaling and insulin sensitivity in vivo (Clement et al.,
001) and was increased in diabetic islets in the present
tudy. Insulin signaling has been shown to stimulate the
xpression of preproinsulin, glucokinase, and other
enes in the β cell, and, in the liver and pancreatic islet,
cts upstream of HNF4α or PDX-1 by stimulating Akt-
ediated phosphorylation of Foxa2 (HNF3β) (Kellerer et
l., 2001; Wolfrum et al., 2003; Lee et al., 2002).
In summary, although much remains to be learned
bout the biology of human pancreatic islets and type
diabetes, our data suggest that changes in gene ex-
ression, and, in particular, changes in ARNT, are likely
o be important in the β cell dysfunction in humans with
ype 2 diabetes. As an obligate partner of several tran-
cription factors involved in the response to toxins and
ypoxic stress, ARNT is at a potential site to integrate
enetic and environmental insults. These findings also
rovide new insights into the pathogenesis of type 2
iabetes and a possible new target for treatment of
his disease.
xperimental Procedures
solated islets were purified from five type 2 diabetic subjects and
even normoglycemic controls using the modified Ricordi method
Ricordi et al., 1988). Average age was 47 years in both groups. The
ean duration of type 2 diabetes was 5.8 ± 2.1 years, and no sub-
ects were insulin requiring. Mean HbA1c was 7.5% ± 0.5% in the
iabetic subjects. There was no difference in islet yield, islet purity,
r islet viability between groups. Islet purity was also compared by
xamining expression of 13 genes reported to best differentiate
slets from acinar tissue (Cras-Meneur et al., 2004). None of these
iffered between the two groups, again suggesting equivalent puri-
ication (Figure 1A).
RNA was extracted from at least 1000 islet equivalents per sub-
ect, and no samples were pooled. cRNA was prepared separately
or each subject (Yechoor et al., 2002) and hybridized to Affymetrix
133A and B microarrays (24 arrays in total). The number of sub-
ects gave an 80% power to detect differences of >1.83 standard
eviations. 1779 cDNA/ESTs represented on the arrays differed
ith p value of <0.05, and 370 differed with p values of <0.01 (the
< 0.01 genes are listed in Table S2). Complete microarray data
ets are available on the Diabetes Genome Anatomy Project
DGAP) website (http://www.diabetesgenome.org).
Real-time PCR was performed in a two-step reaction using the
dvantage RT-for-PCR kit (BD Biosciences, Palo Alto, California).
he second step was performed in a fluorescent temperature cy-
ler (ABI-Prism 7700 Sequence Detection System, Applied Biosys-
ems) with LightCycler-RNA Master SYBR-Green-I (Roche, Mann-
eim, Germany) and specific primers for each of the genes
sequences available on request). Every plate included a control
ene for every subject. Results were analyzed by Student’s un-
aired t test. Semiquantitative PCR of insulin-receptor isoforms
as performed as per Entingh et al. (2003).
iRNA Treatment of Min6 Cells
sing Min6 cells, ARNT mRNA and protein were decreased by 48
r of treatment with small interfering RNAs (Dharmacon), which
ere prepared and transfected using Lipofectamine 2000 (Invitro-
en) according to the respective manufacturers’ protocols to
chieve final siRNA concentrations of 100 nM. siRNA sequences
re available on request. Scrambled-sequence siRNA was used as
control in all experiments (Dharmacon). Following siRNA treat-
ent, ARNT protein was assessed by Western immunoblot using a
onoclonal anti-ARNT antibody (BD Biosciences). Glucose-stim-
lated insulin release was assessed in triplicate wells in three sepa-
ate experiments. In separate experiments, treated cells were lysed
nd RNA isolated for real-time PCR. siRNAs directed against mu-
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347rine HIF1α, HIF2α, and AhR were purchased in “smartpool” form
from Dharmacon and used according to manufacturer instructions.
Each achieved >65% knockdown of the respective expression
(shown in Figure 3G). Knockdown of AhR produced a small de-
crease in basal insulin release, and decreasing HIF1α, HIF2α, and
AhR each led to decreased insulin release at 33 mM glucose (p <
0.01) (Figure 3H). However, the impairment in insulin secretion after
ARNT RNAi was significantly greater than that seen with the other
siRNAs (p < 0.01 for all).
Generation of -ARNT Mice
Whole-body ARNT knockout mice die before embryonic day 10
(Abbott and Buckalew, 2000; Kozak et al., 1997; Maltepe et al.,
1997). To study the effect of deletion of ARNT upon the develop-
ment of diabetes, β cell ARNT knockout mice (β-ARNT) were gener-
ated using the Cre-lox recombination system. Two lox-p sites were
inserted into the ARNT gene flanking exon 4, which contains the
DNA binding domain, as previously described (Tomita et al., 2000).
Homozygous lox/lox mice were interbred with mice expressing Cre
recombinase under control of the rat insulin promoter (RIP-Cre), a
kind gift from Dr. Mark Magnuson. This breeding resulted in mice
with β cell deletion of ARNT (β-ARNT) and floxed control litter-
mates. β-ARNT mice were born at the expected frequencies, were
fertile and did not differ in weight or length.
Glucose-Tolerance Tests and Insulin-Secretion Studies
Glucose-tolerance tests were performed after overnight fasting at
9–11 weeks of age, using either 1 or 2 g/kg of intraperitoneal (i.p.)
glucose as indicated in the figure legend. GTTs were also per-
formed in female mice using a smaller glucose load of 1 g/kg. Glu-
cose-stimulated insulin secretion (GSIS) was assessed following
i.p. injection of 3 g/kg of glucose (Kulkarni et al., 1999a). Arginine-
stimulated augmentation of GSIS was studied following IP injection
of 3 g/kg of glucose plus 0.3 mg/kg of arginine (Kulkarni et al.,
1999a). Insulin was measured by ELISA (Crystal Chem, Chicago).
Islet Immunohistochemistry and Measurement of  Cell Mass
Islets isolated from β-ARNT and control mice were used for immu-
nohistochemical staining for ARNT, insulin, and DAPI (Kulkarni et
al., 1999b). β cell mass was quantified by an observer blinded to
the genotype of the mouse according to the method in Kulkarni et
al. (1999b).
Islet Isolation from -ARNT Mice
Pancreatic islets were isolated from mice aged 10–12 weeks, as
previously described (Kulkarni et al., 1999b). Islet isolation was per-
formed blinded to genotype to avoid bias in islet selection for
secretion studies. The total number of islets isolated from β-ARNT
and control mice did not differ. Equal numbers of islets were sub-
jected to stimulation of insulin secretion at glucose concentrations
of 3.3, 5.5, 8.3, 11, and 25 mM. The remaining islets were reserved
for RNA isolation and quantitative real-time PCR.
Islets from Other Mouse Models of Diabetes
Pancreatic islets were isolated from ob/ob mice, db/db mice, β cell-
specific insulin-receptor knockout mice, and their appropriate con-
trols (obc, dbc, and IR-lox mice) at 10–12 weeks of age. RNA was
isolated and used for real-time PCR to examine gene expression
of ARNT.
Supplemental Data
Supplemental Data include Supplemental References, two tables,
and one figure and can be found with this article online at http://
www.cell.com/cgi/content/full/122/3/337/DC1/.
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